

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.co.jp/>

DAIICHI SANKYO Announces Midterm Management Plan for Fiscal 2007-2009

Tokyo, February 14, 2006 – DAIICHI SANKYO COMPANY LIMITED (hereafter: DAIICHI SANKYO) announced today that it had completed the development of its three-year management plan, starting in fiscal 2007, which serves as the first step towards achievement of the company's long-term vision in 2015. Since the establishment of DAIICHI SANKYO on September 28, 2005, the DAIICHI SANKYO group has been working steadily towards the full integration of its business operations in April 2007. An outline of the plan follows:

Midterm Management Plan

(1) Core Messages

1. Develop infrastructure for the implementation of Vision 2015
2. Optimize synergies of business integration:
 - Strengthen performance in development of new pharmaceuticals and R&D pipeline
 - Develop domestic sales operations to boost income for the group as a whole
 - Maintain and expand key products such as olmesartan medoxomil and levofloxacin
 - Improve efficiency through optimizing personnel and effective operation of group subsidiaries that engage in pharmaceutical businesses.
3. Strengthen of sales performance in the U.S. (increase MRs by a factor of 2.5)
4. Target for fiscal 2009: Operating profit ratio: 25%; Overseas sales ratio: 40% or more
5. Actively pursue return to shareholders
6. Expand businesses through strategic investment

(2) Target figures (Pharmaceutical businesses only)

Fiscal 2007	Sales: ¥820 billion	Operating profit: ¥157 billion (operating profit ratio: 19.1%)
Fiscal 2009	Sales: ¥960 billion	Operating profit: ¥240 billion (operating profit ratio: 25.0%)

(3) Actively pursue return to shareholders

1. Fundamental policy

- Total return ratio target: 100%

Current-term free cash-flow will be appropriated to shareholders' return (dividend and acquisition of treasury stock)

- Early attainment of DOE (dividend on equity ratio) of 5% through stable dividend increase
- Flexible execution of share buyback through Board of Directors' resolution

2. Target figures

- DOE of at least 5% (Fiscal 2006 forecast: 3.5%)

Outline of Vision 2015

(1) Basic vision

- To become a "Global Pharma Innovator"

(2) Target figures

- Sales: ¥1.5 trillion
- Operating profit ratio: 25% or more
- Overseas sales ratio: 60% or more

(3) Key therapeutic areas on which to focus R&D efforts

- To create world-class pipelines for the development of treatments for thrombosis, diabetes, cancer, immunological diseases and rheumatoid arthritis

1st Mid-term Business Management Plan FY2007-FY2009

**First step toward realization of
“Japan based Global Pharma Innovator”**

February 14, 2007


President & CEO Takashi Shoda

Index

- 1. Summary of 1st Mid-term
Business Management plan**
- 2. Research and Development Strategies**
- 3. Domestic Business Strategies**
- 4. Overseas Business Strategies**
- 5. Shareholder Return**
- 6. Summary**
- 7. The current situation of
Main Development Items**



DAIICHI SANKYO CO., LTD.




1-2. Mid-term Business Management Plan Core Messages

- **Improvement and expansion of the growth foundation toward achieving the vision for 2015**
- **Maximization of synergy by management integration**
 - Strengthening of new-drug discovery ability and improvement of the R&D pipeline
 - Building up of domestic sales structure which boosts the profitability of the group as a whole
 - Maintenance and expansion of the major products such as Olmesaltan and Levofloxacin
 - Improvement of business efficiency by appropriate staff allocation and establishment of functional subsidiaries within the group
- **Drastic expansion of sales force in U.S. (2.5 times)**
- **Target for FY 2009 :**
Operating profit ratio 25% Overseas sales ratio 40% or more
- **Active stockholder return**
- **Business expansion through strategic investment**

2

DAIICHI SANKYO CO., LTD.

1-3. Numerical target from FY 2007 to FY 2009




Exchange rate for overseas business
1 \$ = 115¥, 1 Euro = 140¥

(Note) * As for FY 2006, figures are quoted from the released account settlement
• Based on the figures for U.S. subsidiaries (DSI, LPI) where 15 months were reported due to the change of settlement period, accounts from January 2006 to March 2006 were deducted.
• Figures for all non-pharmaceutical businesses were deducted.


3

DAIICHI SANKYO CO., LTD.

1-4. Creation of cost synergy by integration



1-5. Olmesartan is the growing driver for the midterm account settlement



* For sales figures of Olmesartan for FY 2006, those from January to March in U.S. are deducted .
 * Sales figures of Olmesartan for FY 2009 include those of CS-8663.

DAIICHI SANKYO CO., LTD.

1-6. Target of Profits and losses

■Target for FY 2009: Operating profit ratio of 25%

Product Name	FY2006(Prospects)		FY2007 (Target)		FY2009 (Target)	
	(billion yen)	(%)	(billion yen)	(%)	(billion yen)	(%)
Sales	785	100.0	820	100.0	960	100.0
Cost+SGA	665	84.7	663	80.8	720	75.0
R&D cost	160	20.4	155	18.9	165	17.2
Operating profit	120	15.3	157	19.1	240	25.0

(Note) *As for FY 2006, figures are quoted from the released account settlement

• As for figures for U.S. subsidiaries (DSI, LPI) where 15 months were reported due to the change of settlement period, those from January to March were deducted

• Figures for all non-pharmaceutical businesses were deducted.

 DAIICHI SANKYO CO., LTD.

6

1-7.1 2015 Vision

“Global drug-discovery-oriented company”
Realization of Global Pharma Innovator

■Global

- Company conducting business from major bases around the world.

■Drug-discovery oriented company

- Company continuously focusing on pharmaceutical business and the creation of innovative pharmaceutical products

 DAIICHI SANKYO CO., LTD.

7

1-7.2 2015 Vision

■ Pursuit of achievements worthy of a global company

Target figures for FY 2015

- Sales 1.5 trillion yen
- Operating profit margin 25% or more
- Overseas sales ratio 60% or more

■ Priority diseases in research and development

- Thrombosis, Diabetes, cancer, autoimmune disease/ rheumatoid arthritis

Establish a pipeline among the global top class


8

DAIICHI SANKYO CO., LTD.

1-7.3 Process toward the a goal of 2015 vision

First Mid-term Business Management Plan

Expansion of the base for growth
toward achieving the visions for 2015



9

DAIICHI SANKYO CO., LTD.



2-1. Research and development , interim target

- Establish a global R&D development system
- Improvement of R&D pipeline
- Make a R&D development foundation by strategic investment

10

DAIICHI SANKYO CO., LTD.

2-2. Items scheduled for application during this term

Region	Under application	Items scheduled for application	
Japan Asia	DU-6859a (Gracevit)	CS-866AZ	CS-8958
	CS-1401E (Fentanest for pediatric use)	SUN Y7017 (Memantin)	DS-992 (HGF)
	LX-P (Loxonin tape)	Cravit high-dose	Kremezin (China)
		KMD-3213 (Urief China)	CS-866HCTZ (China)
		Etc	
U.S.	CS-8663	CS-747 (Prasugrel)	
	WelChol DM (Diabetes)	Etc	
Europe		CS-8663	
		CS-747 (Prasugrel)	
		Etc	

Novel component

Additional formulation and additional indication, etc.



DAIICHI SANKYO CO., LTD.

11

2-3. Major new products scheduled for release during this term

Region	Items	
Japan Asia	DU-6859a (Gracevit)	HIB Vaccine
	Cravit high-dose	LX-P (Loxonin tape)
	KMD-3213 (Urief China)	Kremezin (China)
	CS-866HCTZ (China)	Sunrhythm (Korea)
U.S.	CS-8663	WelChol DM (Diabetes)
	CS-747 (Prasugrel)	
Europe	CS-8663	CS-747 (Prasugrel)

Novel component


Additional formulation and additional indication, etc.



DAIICHI SANKYO CO., LTD.

12

2-4. Global R&D bases



3 Domestic Business Strategies

3-1. Ethical drug business, Gist of the midterm strategies

- Sales synergy by the new domestic sales structure
- Input sales and marketing resources into the priority product group (Olmotec, Cravit, Mevalotin, etc.) preferentially
- Place Olmetec and Cravit as growth driver
- Improvement of the product value by reinforcing the lifecycle management



Target for FY 2009 Sales **470** billion yen

14

 **DAICHI SANKYO CO., LTD.**

3-2. Indication of integration synergy and productivity improvement

- **Start-up with top speed through the new domestic sales structure**
 - Unification of Sales formation and development of marketing and wholesale strategies from the first year of integration in order to maximize the sales synergy
 - Staffing of 2,300 MRs
Promote the dissemination activities of the domestic top-level academic information both in quality and quantity
 - Collaboration between the “site MR” line and “area MR” line
- **Improvement of the productivity of MRs(based on the current NHI price)**
 - Target for FY2007: Increase of sales productivity per person by 25% (compared with FY 2006)
 - Target for FY 2009: Sales per person exceeding 250 million yen

15

 **DAICHI SANKYO CO., LTD.**

3-3. Sales target for the priority product field

Field	Product	Prospect for FY 2006	Target for FY 2009
Cardiovascular disease-related field	10 products including Olmetec, Artist, Calblock, Mevalotin, Livalo, Kremezine, Fastic	185 billion yen	230 billion yen
Infectious diseases/ bone/joints/ Immune system/allergy/ urology	Cravit, Loxonin brand, Mobic, Zyrtec, Urief	105 billion yen	120 billion yen
Contrast agents/cancer/ gastric diseases	Omnipaque, Omniscan, Topotecin, Krestin, Feron	50 billion yen	50 billion yen

16

DAIICHI SANKYO CO., LTD.

3-4. Midterm plans of Daiichi Sankyo Healthcare (DSHC)

■ Strategies

- Building-up the franchise in the field of expertise where several brands including "general cold remedy" and "gastrointestinal drugs" are offered
- Establishment of the new growth foundation by undertaking the new business development and collaboration and the active development of the new field (functional skin-care, functional food)
- Improvement of business management efficiency by implementing cost operation

■ New products scheduled for release

- Windom (athlete's foot remedy), Skin-care related products, etc.

■ Number of employees

- 390 people structure (reduction by approximately 25% compared to the previous year*) Staffing of 150 MRs

■ Target for FY 2009: Sales of 58 billion yen

Operating profit 10% or more

*Daiichi-Sankyo Healthcare + Zepharm

DAIICHI SANKYO CO., LTD.

17



4 Overseas Business Strategies



DAIICHI SANKYO CO., LTD.

4-1. Gist of the overseas business strategies

- Enhancement of the sales foundation toward the sales expansion of Olmesartan and the marketing of new products around Europe and U.S.
- Securing of the profit foundation by exporting drug substances including Levofloxacin
- Expansion of the business foundation in Asian and Latin American regions

4-2.1 Midterm plans of Daiichi Sankyo Inc.(DSI)

■ Strategies

- Continuing strong growth of already-marketed products
- Achievement of the effective sales force expansion
- Preparation of a structure for the release of new products

■ New products marketing plan


- CS-8663 (combination preparation of Olmesartan and Amlodipine)
- WelChol DM (additional indication for Type 2 diabetic treatment)
- Prasugrel (antiplatelet agent)

■ Progressive enhancement of the sales personnel

900 people structure⇒2,300 people structure (FY 2009)

■ Target for FY2009: Sales of 200 billion yen or more

(1 billion yen) Sales Trend of DSI



19

DAIICHI SANKYO CO., LTD.

4-2.2 Expansion of the sales force toward the rapid growth in U.S.

FY 2007				FY 2008				FY 2009			
1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q

Topics


★Release of CS—8663
(Olmesartan+Amlodipine)

★Release of Prasugrel

★Application of Prasugrel

★Release of WelChol(diabetes)

Sales
personnel
enhancement
plan



※1Q of FY 2007 means the months from April to June and it's the same for other fiscal years

20

DAIICHI SANKYO CO., LTD.

4-2.3 Midterm plans of Luitpold Inc. (LPI)

■ Strategies

- Maintaining of the sales of Venofer (therapeutic agent for anemia)
- Enhancement of the sales force toward the release of new products such as VIT-45 (Venerfer's succession) (Prior investment from 2007 to 2008)
- Reinforcement of the Osteohealth sector (business sector handling dental materials)

■ Enhancement of the sales personnel

- 50 people structure ⇒ 350 people structure (2009)

■ Target for FY 2009: Sales of 60 billion yen or more

21

DAIICHI SANKYO CO., LTD.

4-3. Midterm plans of Daiichi Sankyo Europe (DSE)

■ Strategies

- Enhancement of the sales force for the release of new products
- Establishment of the specialist team in the cardiovascular area toward the release of Prasugrel


■ New products scheduled for release

- CS-8663 (combination preparation of Olmesartan and Amlodipine)
- High-dose preparation of Olmetec Plus (combination preparation of Olmesartan and diuretic)
- Prasugrel (antiplatelet agent)

■ Progressive enhancement of the sales personnel

800 people ⇒ 1,000 people structure (2009)

■ Target for FY2009: Sales of 70 billion yen or more



22

DAIICHI SANKYO CO., LTD.

4-4. Asian and Latin American businesses Gist of the midterm plans

■ Deploy the expansion strategy focused on Olmesartan in respective countries

- China Synergy by collaboration of 2 companies (Daiichi Pharmaceuticals Beijing and Shanghai Sankyo)
- Taiwan Expansion of the already-marketed products by the integrated new company, release of new products such as CS-8663
- Korea 100% subsidiary company since October 2006
Build up the foundation in the cardiovascular area
- Brasil • Venezuela Olmesartan (single agent, combination preparation of Olmesartan and diuretic), Sales expansion of CS-8663

■ Maintenance and expansion of Levofloxacin in Asia

■ Establishment of the new company in India (scheduled during 2007)

- Strengthening of collaboration with Uni-Sankyo (local joint venture, 39.99% investment)


■ Target for FY 2009: Sales of 25 billion yen

23

DAIICHI SANKYO CO., LTD.

4-5. Establishment of the sales foundation based on the global tetra-polar structure

■ FY2009 Sales and MR (sales representative) workforce planning



24

DAIICHI SANKYO CO., LTD.



5 Shareholder Return

DAIICHI SANKYO CO., LTD.

5-1. Shareholder Return


■ Midterm policies

- Free cash flow for the term will be appropriated to shareholder return (dividends + share buy back)
⇒ "Total Return Ratio" target: 100%
- Early achievement of DOE 5% and implementation of stable increase in capital
- Share buy back will be conducted flexibly based on the resolutions at the board of directors' meeting

Target for FY2009

FY2006
Annual dividend 60yen

**DOE
3.5%**




**DOE
5% or more**

ROE 10% or more, payout ratio around 50%
DOE (Dividend on Equity) = payout ratio × ROE

	FY 2006 (Prospects)	FY 2009 (Target)
EPS	97 yen	More than doubled
ROE	5.7%	10% or more

25

DAIICHI SANKYO CO., LTD.




6-1. Summary

- Maximization of synergy (sales, cost) by the management integration
- Strengthening of R&D capability toward achieving the vision for 2015 and prior investment to the U.S.
- Improvement of the pipelines
- Accomplishment of the operating profit ratio of 25% and the overseas sales ratio of 40% or more
- Active shareholder return


26

DAIICHI SANKYO CO., LTD.




7 The current situation of Main Development Items

**GEMRAD chairman
John C. Alexander**

 **DAIICHI SANKYO CO., LTD.**

7-1. R&D Integration

- **GEMRAD (R&D management meeting) began in Oct. 2005**
- **US/EU integration completed in April 2006**
- **Global R&D Strategy meeting in Jan. 2007**
- **Full R&D integration in April 2007**

 **DAIICHI SANKYO CO., LTD.**

27

7-2. List of major developed items

	Candidate for development	Phase 1	Phase 2	Phase 3	Under application
Cardiovascular disease		<u>DZ-697b</u>	<u>DU-176b</u> CS-866RN(#) CS-866CMB(#) SUN 4936h	<u>CS-747</u> HGF CS-866DM (#) CS-866AZ (#)	<u>CS-8663</u>
Glucose metabolism		SUN E7001 (#) AJD101	CS-011 CS-917		WelChol DM
Infectious diseases		DX-619 CS-758 CS-8958 DC-159a	[CS-023]		DU-6859a DF-098 (#) [SUN A0026]
Cancer	DE-766(#)	CS-7017 CS-1008			
Immunity • allergy		CS-0777	CS-712 (#)		
Bone • joints	OCIF		CS-706 SUN E3001 (#)	CS-600G (#)	LX-P (#)
Other	CS-011 (#) (dry eyes)	SUN N8075	SUN N4057 CS-088 KMD-3213 SUN11031	SUN Y7017 (#) DL-8234(#) [SUN0588r]	CS-1401E (#) DL-404 (#)

• #: Developed only in Japan
• []: Derivation

• For items that are being developed on a global basis (outside of Japan), the most advanced stage is described.
• The underlined items are the current projects with the highest priority.

DAIICHI SANKYO CO., LTD.

28


7-3.1 Prasugrel (CS-747)

- Co-developing & co-commercializing with Eli Lilly and Co.
- Platelet aggregation inhibitor
 - Initial submission for acute coronary syndromes (ACS)
- Phase 1 studies suggest prasugrel may have superior profile
 - Higher inhibition of platelet aggregation (IPA)
 - Faster onset of IPA
 - More consistent IPA
- Phase 2 safety study indicated acceptable bleeding profile

DAIICHI SANKYO CO., LTD.

29

7-3.2 Prasugrel - Higher IPA than High Loading Dose of Plavix -



30

DAIICHI SANKYO CO., LTD.

7-3.3 Prasugrel - Summary of Phase3 (TRITON) Study -

■ TRITON study background

- Superiority head-to-head vs. Plavix
- Event-driven trial
- Hope to demonstrate faster onset, higher IPA, more consistent response yields improved clinical outcomes versus Plavix

■ TRITON update

- Completion of enrollment in January with 13,600 patients

**Tracking for mid year study completion;
NDA filing by end 2007**

31

DAIICHI SANKYO CO., LTD.

7-4. CS-8663

■ A fixed dose combination of two antihypertensives, amlodipine (most widely used CCB) and olmesartan medoxomil (fastest growing ARB)

- ARBs continue to be the fastest growing anti-hypertensive class
- Life cycle management strategy to grow Benicar(US) / Olmetec(Europe) franchise

■ Target indication : second line therapy for hypertensive patients who fail monotherapy

- Over 120 million hypertensive patients in the US/EU and still growing
- Only 40 - 50% of hypertensive patients are being treated, and only about half of them achieving target blood pressure goals
- Addresses unmet medical need, getting more patients to treatment goals recommended by the guidelines

■ NDA in the US, November 2006

- NDA target in EU, autumn 2007

32

 DAIICHI SANKYO CO., LTD.

7-5.1 DU-176b - Unmet Medical Needs for Oral Anticoagulants -

■ Consistent drug response (No monitoring required)

■ Improved risk/benefit in DVT and NVAf

DVT: deep venous thrombosis, NVAf: nonvalvular atrial fibrillation

■ Faster onset of action

■ No drug-drug interactions

■ No drug-food interactions

33

 DAIICHI SANKYO CO., LTD.


7-5.2 DU-176b

- Best in class inhibitor of blood coagulation factor Xa
- No hepatotoxicity signals in pre-clinical including toxicogenomics and clinical studies
- Phase 2b studies in patients with total hip replacement and total knee replacement are on going
- Phase 2b study in NVAf is under preparation
- Significant market opportunity but with competitors

34

DAIICHI SANKYO CO., LTD.

7-5.3 DU-176b *Ex vivo* Study in human



Once a day dosing was suggested in human volunteers.

35

DAIICHI SANKYO CO., LTD.

7-5.4 Profile and Positioning of DU-176b

Attributes	DU-176b
<i>Dosage Regimen</i>	Once a day dosing
<i>Efficacy</i>	Not inferior to warfarin in DVT and NVAF
<i>Safety and tolerability</i>	
- Bleeding	Not inferior to warfarin
- Liver Toxicity	No hepatotoxicity (superior to competitors)
<i>Indications</i>	DVT NVAF
<i>Food Effects</i>	No
<i>Monitoring</i>	No

36

DAIICHI SANKYO CO., LTD.

7-6. DZ-697b

■ First in class anti-platelet agent

- Inhibit high-shear stress induced platelet aggregation
- Inhibition is reversible
- Little inhibition on aggregation at low-shear stress, suggests lower bleeding risk

■ Phase 1 study

- Rapid onset and prolonged inhibition
- Inhibit platelet aggregation induced by shear stress
- Excellent PK profiles in oral absorption and AUC, not influenced by food intake or ethnicity
- Less safety concern in combination with aspirin
- Inhibit ex vivo Badimon chamber thrombosis model in human

■ Phase 2a studies are under preparation

- Phase 2a study is to initiate in 2007
- Targets: Stroke/TIA, ACS

■ Potential Indications

Stroke, ACS, Microcirculation disorders

37

DAIICHI SANKYO CO., LTD.

7-7.1 Diabetes Franchise

WelChol DM (Expansion of indication for diabetes in the US)

- WelChol contains colestevlam hydrochloride, a non- absorbed, polymeric, lipid-lowering agent intended for oral administration
- The result of three Phase 3 studies concomitant with other hypoglycemic agents indicates that WelChol is effective for inadequately controlled type 2 diabetes patients with the existing treatments
- Supplemental NDA submission made on December, 2006

CS-011 rivoglitazone

- Potent selective PPAR-gamma agonist for treatment of diabetes
- Goal is to achieve superior glycemic control and safety compared to pioglitazone (Best in Class)
- Dose-dependent efficacy on plasma glucose and lipid parameters superior to pioglitazone were demonstrated in Phase 2b study
- Carcinogenicity studies are on-going
- Discussion with FDA for Phase 3 studies

38

DAIICHI SANKYO CO., LTD.

7-7.2 Diabetes Franchise

CS-917

- First in class, the fructose 1-6 biphosphatase (FBPase) inhibitor
- FBPase is a rate-limiting enzyme that regulates hepatic glucose production
- Potential to treat a majority of type 2 diabetic patients as monotherapy or in combination with other therapies
- Proof of concept was established with reduction in fasting plasma glucose
- Phase 2b study with low dose range for safety has completed enrollment with no evidence of lactic acid level increase to date

AJD101

- Licensed from Ajinomoto Co., Inc. in August, 2006
- Anti-diabetic agent with new mechanism
- Four Phase 1 trials completed in EU and AJD101 was well tolerated and safe for healthy volunteers and patients
- Phase 2a study is planned in Japan and mechanistic study planned in EU
- Development exclusively outside Japan, co-development with Ajinomoto in Japan

39

DAIICHI SANKYO CO., LTD.

Contact information for inquiries regarding this material

DAIICHI SANKYO CO., LTD.
Corporate Communications Department

TEL: 03-6225-1126
FAX: 03-6225-1132

Numerical values for future projections in this material are derived from our judgments and assumptions based on the currently available information and they include risks and uncertainty. For this reason, the actual results may differ from the projected numerical values.

